US/UK/Canada

Share

Contacts

  • Iohn Ryott

    COO


    Industrivägen 1 171 48 Solna
    +46707433479
  • Pelle Redare

    CEO


    Industrivägen 1 171 48 Solna
    +46708178828
    • Pick a time period -
    Tags ( Active)

    iCellate welcomes Per Öhrn as new Director of Sales

    Stockholm, Sweden – February 12, 2024 – iCellate strengthen the commercial team by adding Per Öhrn as Director of Sales. Per brings a wealth of experience from various sales roles in Sweden and Europe.iCellate is delighted to announce that Per Öhrn has joined iCellate as our new Director of Sales, effective January 8, 2024. Per brings with him a wealth of experience and expertise in the MedTech and Pharma industry, along with a proven track record of driving sales and fostering growth in the Nordic region. With over 25 years of experience, Per has held significant leadership roles,

    iCellate Medical receives first patient sample in METRO trial

    Stockholm, Sweden – December 15, 2023 – iCellate continues validation of its circulating tumor cell (CTC) platform CellMate® across various cancer indications. This week we have included the first patient samples in the METRO trial, a multicenter, prostate cancer, phase III trial run in Sweden.CellMate® is a circulating tumor cell (CTC)-based platform for early cancer cell detection and biomarker analysis. The isolation of CTCs in the blood provides for a more comprehensive analysis of genomic and protein biomarkers to support treatment selection. Clinical practice for diagnosis and

    iCellate Medical receives first patient samples in two new clinical studies

    Stockholm, Sweden – October 3, 2023 – iCellate continues validation of its circulating tumor cell (CTC) platform CellMate® across various cancer indications. This week we anticipate including the first patient samples in two new studies, a prostate study in collaboration with Capio Urology Center in Liljeholmen, Sweden and a pancreatic study together with Karolinska University Hospital in Huddinge.Clinical evidence is currently in focus for iCellate, i.e. more data to support the commercial efforts in establishing CellMate® as a companion diagnostic in pharma development projects and using

    Information on notice of extraordinary general meeting of iCellate Medical AB (556860-8284) (publ)

    The shareholders of iCellate Medical AB (publ) are hereby informed that the company has issued notice of an extraordinary general meeting on 27 October 2023 at 1:00 p.m. The meeting takes place at Industrivägen 1 in Solna.The notice has taken place through advertising in Post- and Inrikes Tidningar and by making the notice available on the company's website; www.icellate.com. The notice is sent free of charge to shareholders who request it and state their postal address. Such a request can be made in the same way as notification to the general meeting must be made as described below.

    iCellate Medical discontinues direct-to-consumer sales of its GeneMate® service

    Stockholm, Sweden – July 6, 2023 - iCellate Medical discontinues D2C sales of its GeneMate® service. GeneMate® combines DNA sequencing with an analysis of family cancer history to provide a comprehensive assessment of an individual’s hereditary cancer risk. The service will be discontinued as the company focuses its resources on its CellMate® platform for detection and analysis of circulating tumor cells (CTCs). CellMate® is developed for early cancer detection and precision diagnostics.GeneMate® has primarily been marketed directly to consumers in Sweden and the UK since its launch in 2021,

    iCellate Medical secures 20 MSEK in new funding

    Stockholm, Sweden – June 8, 2023 - iCellate Medical has closed a successful round of financing, raising 20 MSEK from a combination of existing and new investors. iCellate develops cancer tests for early detection, treatment selection, and hereditary cancer risk.iCellate is a privately held life sciences company, spearheading the industry in cancer profiling. Through liquid biopsy tests, the analysis of tumor-derived material in the blood or saliva, iCellate paves the way for precision medicine to reach more patients. Ongoing clinical studies investigating iCellate’s CTC-based technology,

    Karolinska University Hospital welcomed as new site in expansion of Horizon 2020 project DeteCTCs

    Stockholm, Sweden – April 18, 2023 – iCellate is excited to announce the expansion of the Horizon 2020 project, DeteCTCs, to Sweden with the addition of clinical site Karolinska University Hospital led by principal investigator Matthias Löhr. The DeteCTCs project is led in collaboration with QIAGEN and University Medical Center Schleswig-Holstein.iCellate, QIAGEN, and University Medical Center Schleswig-Holstein were awarded 2.4 million euro from European Funding Agency, Horizon 2020 in February 2021. The ongoing project aims to make iCellate’s CTC platform CellMate® available to cancer

    iCellate Medical Ramps Up Prostate Study with Capio Urology Center

    Stockholm, Sweden – April 18, 2023 – iCellate continues validation of its circulating tumor cell (CTC) platform CellMate® across various cancer indications. In collaboration with Capio Urology Center in Liljeholmen, Sweden, iCellate launches study to investigate the clinical value of CTC analysis in prostate cancer patients at various stages of disease.Despite prostate cancer being one of the most common cancers in men, the question of whether to implement prostate cancer screening remains unanswered. As is the case for many cancers, the characterization and treatment of prostate cancer is

    iCellate joins METRO study with aim of analyzing circulating tumor cells (CTCs) in prostate cancer

    Stockholm, Sweden – March 21, 2023 – iCellate joins as new study partner in the METRO study and will use its liquid biopsy technology for biomarker analyses in oligometastatic prostate cancer patients. The METRO consortium is comprised of eight Swedish hospitals including university hospitals (all but Linköping and Uppsala),  Ryhov Hospital, Södersjukhuset, and Sankt Göran in Stockholm. Karin Söderkvist of Umeå University Hospital is the lead Principal Investigator.The study will recruit patients with oligometastatic prostate cancer. Standard of care therapy (SOC) will be compared with SOC

    The Horizon 2020 project DeteCTCs initiates clinical study for development of next generation CTC-based cancer diagnostics

    Stockholm, Sweden. May 24, 2022. iCellate Medical AB, in association with the University Medical Center Schleswig-Holstein and QIAGEN, Inc. are proud to announce that the clinical study portion of their joint project DeteCTCs, subsidized by the EU Horizon 2020 programme, has included its first study subject.We are excited to announce the enrollment of the first subject into the clinical study portion of the DeteCTCs project, to accelerate the continued development of iCellate’s next-generation CellMate[®] in vitro diagnostic platform. Over two years, this study will enroll approximately 260

    iCellate Medical secures 20 MSEK in new funding

    Stockholm, Sweden - 19 May 2022 - iCellate Medical has closed a successful round of financing, raising 20 MSEK from a combination of existing and new investors. iCellate develops tests for hereditary cancer risk, early cancer detection, and treatment selection.iCellate is a privately held biotechnology company, leading the industry in cancer diagnostics. Through liquid biopsy tests, where the analysis of tumor-derived material in the blood, iCellate paves the way for precision medicine to reach more patients. Ongoing clinical studies in various cancer types (prostate, pancreatic, ovarian,

    iCellate and Aptadel awarded Eurostars grant of 10 MSEK for novel cancer treatment and companion diagnostic

    Stockholm 17 March 2022 – iCellate Medical, a Swedish genomic cancer diagnostics company and Spanish therapeutics company Aptadel have been awarded a grant of 10 MSEK from Eurostars for a first in-class RNA Aptamer-based targeted therapy for childhood cancer Ewing Sarcoma.For the second time in two years, iCellate has been awarded a substantial grant from Eurostars. As with the grant from 2020, for the Elevate project, iCellate will develop a new class of biomarker tests based on liquid biopsy to select patients for treatment with a new targeted cancer therapy. The Swedish government agency,

    Project ELEVATE initiates clinical trial for development of novel cancer diagnostics

    February 10, 2022. Elthera AG, iCellate Medical AB, Targos Molecular Pathology GmbH and Prof. Dr. Susanne Sebens at the Institute of Experimental Cancer Research (IET) at the University of Kiel are proud to announce that the clinical trial for their joint project ELEVATE, funded by the EUREKA Eurstars programme, has commenced.We are excited to enroll the first subject into the ELEVATE clinical trial. Over the next two years, this trial aims to enroll approximately 200 subjects with colorectal or pancreatic cancer, as well as 50 healthy controls. Tumor and liquid biopsy samples will be

    iCellate Expands Headquarters

    Stockholm, Sweden – January 17, 2022 - iCellate Medical AB, a Swedish cancer diagnostics company, is happy to announce the 300 m[2] expansion of its headquarters at Industrivägen in Solna just outside of Stockholm. The expansion comes as a natural next step in the company’s journey and allows for automation and scaling up of laboratory processes for the GeneMate[®] product.Four years ago, iCellate moved from the area near The Karolinska Institute to Hagalund’s industrial park. Humlegården has been an accommodating landlord through the years, allowing for a smooth expansion of the company’s

    Elthera-led consortium initiates development of novel cancer diagnostics and therapeutics

    November 24, 2020. Elthera AG, iCellate Medical AB, Targos GmbH and Prof. Dr. Susanne Sebens at the Institute of Experimental Cancer Research (IET) at the University of Kiel are proud to announce that they have received a non-dilutive grant with a total budget of 2.7 M € from the EUREKA Eurostars programme. The grant will allow the consortium to finalize the preclinical development of Elthera’s proprietary anti-L1CAM antibody and to develop novel L1CAM-based solid and liquid biopsy methods for patient selection and treatment monitoring in clinical trials.The consortium partners bring

    The early detection of cancer study (ICELLATE1) – published in the Journal of Integrative Oncology

    Stockholm, Sweden – September 21, 2018 – iCellate today announce that yet another important observational study, termed Screening Circulating Tumor Cells as a Non-invasive Cancer Test in 1,585 Asymptomatic Adults (ICELLATE1), has been published in the Journal of Integrative Oncology.iCellate, a Swedish medtech company active in the field of cancer management, in collaboration with Hospital Nacional Arzobispo Loayza in Lima, has conducted an all-comers, single center study that includes individuals in the age bracket 20-80 years that do not belong to any known risk group for cancer, and who

    iCellate Medical raises 16 MSEK in new equity to demonstrate its clinical validity and utility

    Stockholm, Sweden – June 30, 2018 – iCellate Medical has raised 16 MSEK in new equity, from both existing and new shareholders. iCellate’s mission is to detect cancer early, when it can still be cured, and to guide individual therapies. iCellate, a privately held Swedish medtech company, is an innovation leader in the fields of cancer diagnostics and cancer management. 10 out of the 16 MSEK came from new shareholders, expanding the owner base, of which the following should be noted; “Albert & Annas minne” foundation (descendants to the founder of Sandvik AB) and Stassi Anastassov (a

    Groundbreaking pan-cancer screening study published

    Solna, Sweden – May 29, 2018 –Baseline data from iCellate’s groundbreaking screening study – Screening Circulating Tumor Cells as a Noninvasive Cancer Test in 3388 Individuals from High-Risk Groups (ICELLATE2) – has been published in the May issue of the journal Disease Markers. iCellate, in collaboration with Hospital Nacional Arzobispo Loayza in Lima, has conducted an all-comers, single center study in a high-risk population (smokers, cancer heredity, hepatitis B or positive PSA) of 3388 subjectively healthy individuals to investigate if screening for CTC (circulating tumor cells) in

    There are no items matching the current filter
    There are no more items matching the current filter
    Back to top

    Subscribe

    Media